A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure

• Published in: Vaccine Vol. 24; no. 26; pp. 5481 - 5490
• Main Authors: Antonis, Adriaan F.G., Bruschke, Christianne J.M., Rueda, Paloma, Maranga, Luis, Casal, J. Ignacio, Vela, Carmen, Hilgers, Luuk A. Th, Belt, Peter B.G.M., Weerdmeester, Klaas, Carrondo, Manuel J.T., Langeveld, Jan P.M.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 29.06.2006; Elsevier; Elsevier Limited
• Subjects: adjuvants; Adjuvants, Immunologic; Animals; Antigens; Applied microbiology; Baculovirus; baculovirus vectors; Biological and medical sciences; canine parvovirus; coinfection; disease; Dose-Response Relationship, Drug; experimental-infection; Failure; Female; Fundamental and applied biological sciences. Psychology; Guinea Pigs; immune-responses; Immunization; Immunogenicity; Infections; Medical research; Microbiology; Mineral oils; Miscellaneous; Parvoviridae Infections - prevention & control; Parvoviridae Infections - veterinary; Parvovirus, Porcine - immunology; pigs; Porcine parvovirus; Pregnancy; pregnant gilts; Recombinant; Studies; Swine; Swine Diseases - prevention & control; Vaccine; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral Vaccines - adverse effects; Viral Vaccines - immunology; Virology; Virus-like particles; volunteers; Vaccine; Virus-like particles; Porcine parvovirus; Recombinant; Virus; Prevention; Parvovirus; Parvoviridae; Recombinant virus; Virus like particle; Failure; Parvovirinae
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2006.03.089

A novel vaccine against porcine parvovirus (PPV), composed of recombinant virus-like particles (PPV-VLPs) produced with the baculovirus expression vector system (BEVS) at industrial scale, was tested for its immunogenicity and protective potency. A formulation of submicrogram amounts of PPV-VLPs in a water-in-mineral oil adjuvant evoked high serum antibody titres in both guinea pigs, used as reference model, and target species, pigs. A single immunisation with 0.7 μg of this antigen yielded complete foetal protection against PPV infection after challenge with a virulent strain of this virus. Furthermore, also in the presence of mild adjuvants the protective action of these PPV-VLPs is excellent. This recombinant subunit vaccine overcomes some of the drawbacks of classical PPV vaccines.